Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity

Biological Psychiatry

Volumn 55, Issue 11, 2004, Pages 1103-1109

  Seager, Matthew A ^a   Huff, Keith D ^a   Barth, Vanessa N ^a   Phebus, Lee A ^a   Rasmussen, Kurt ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antidepressant; depression; fluoxetine; locus coeruleus; norepinephrine; olanzapine

Indexed keywords

FLUOXETINE; OLANZAPINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CELL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; IMPLANT; LOCUS CERULEUS; MALE; NEUROMODULATION; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; RAT; RECORDING; SIGNAL TRANSDUCTION; SINGLE UNIT ACTIVITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ACTION POTENTIALS; ANALYSIS OF VARIANCE; ANIMALS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; FLUOXETINE; LOCUS COERULEUS; MALE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 2542455867     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2004.02.012     Document Type: Article

References (47)

1. Bergstrom R.F., Callaghan J.T., Cerimele B.J., Kurtz D.L., Hatcher B.L. Population pharmacokinetics and plasma concentrations of olanzapine. Tran P.V., Bymaster F.P., Tye N., Herrera J.M., Breier A., Tollefson G.D. Olanzapine (Zyprexa) A novel antipsychotic. 2000;232-252 Lippincott Williams & Wilkins, Philadelphia
2. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96
3. Bymaster F.P., Zhang W., Carter P., Shaw J., Chernet E., Phebus L., et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology. 160:2002;353-361
4. Consolo S., Baldi G., Russi G., Civenni G., Bartfai T. Impulse flow dependency of galanin release in vivo in the rat ventral hippocampus. Proc Natl Acad Sci U S A. 91:1994;8047-8051
5. Crewe H.K., Lennard M.S., Tucker G.T., Woods F.R., Haddock R.E. The effect of selective serotonin re-uptake inhibitors on cytochrome P450D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 34:1992;262-265
6. 2A receptor signaling in frontal cortex, oxytocin- and corticotropin-releasing factor-containing neurons in rat paraventricular nucleus. J Pharmacol Exp Ther. 306:2003;563-571
7. Dawe G.S., Huff K.D., Vandergriff J.L., Sharp T., O'Neill M.J., Rasmussen K. Olanzapine activates the rat locus coeruleus In vivo electrophysiology and c-Fos immunoreactivity. Biol Psychiatry. 50:2001;510-520
8. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry. 61:(suppl 1):2000;26-32
9. Floresco S.B., West A.R., Ash B., Moore H., Grace A.A. Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission. Nat Neurosci. 6:2003;968-973
10. Florin-Lechner S.M., Druhan J.P., Aston-Jones G., Valentino R.J. Enhanced norepinephrine release in prefrontal cortex with burst stimulation of the locus coeruleus. Brain Res. 742:1996;89-97
11. Gobert A., Rivet J.-M., Cistarelli L., Millan M.J. Buspirone enhances duloxetine- and fluoxetine-induced increases in dialysate levels of dopamine and noradrenaline, but not serotonin, in the frontal cortex of freely moving rats. J Neurochem. 68:1997;1326-1329
12. Gossen D., de Suray J.-M., Vandenhende F., Onkelinx C., Gangji D. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci. 4:(2):2002;E11
13. Grace A.A., Bunney B.S. The control of firing pattern in nigral dopamine neurons. J Neurosci. 4:1984;2877-2890
14. Graham A.W., Aghajanian G.K. Effects of amphetamine on single cell activity in a catecholamine nucleus, the locus coeruleus. Nature. 234:1971;100-102
15. Grant M.M., Weiss J.M. Effects of antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiological activity. Biol Psychiatry. 49:2001;117-129
16. Grenhoff J., Nisell M., Ferre G., Aston-Jones G., Svensson T.H. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J Neural Tansm Gen Sect. 93:1993;11-25
17. Hatanaka K., Yatsugi S., Yamaguchi T. Effect of acute treatment with YM992 on extracellular norepinephrine levels in the rat frontal cortex. Eur J Pharmacol. 395:2000;31-36
18. Hirschfeld R.M.A., Montgomery S.A., Aguglia E., Amore M., Delgado P.L., Gastpar M., et al. Partial response and nonresponse to antidepressant therapy Current approaches and treatment options. J Clin Psychiatry. 63:2002;826-837
19. Jordan S., Kramer G.L., Zukas P.K., Moeller M., Petty F. In vivo biogenic amine efflux in medial prefrontal cortex with imipramine, fluoxetine, and fluvoxamine. Synapse. 18:1994;294-297
20. Kassahun K., Mattiuz E., Nyhart E. Jr, Obermeyer B., Gillespie T., Murphy A., et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 25:1997;81-93
21. Kuroki T., Meltzer H.Y., Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther. 288:1999;774-781
22. Li X.-M., Perry K.W., Wong D.T., Bymaster F.P. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology. 136:1998;153-161
23. 2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. Psychopharmacology. 133:1997;99-101
24. Matthews J.D., Bottonari K.A., Polania L.M., Mischoulon D., Dording C.M., Irvin R., et al. An open study of olanzapine and fluoxetine for psychotic major depressive disorder: Interim analysis. J Clin Psychiatry. 63:2002;1164-1170
25. Nasif F.J., Cuadro G.R., Ramirez O.A. Effects of chronic risperidone on central noradrenergic transmission. Eur J Pharmacol. 394:2000;67-73
26. Ostroff R.B., Nelson J.C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry. 60:1999;256-259
27. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed:1998;Academic Press, San Diego
28. 4 and microdialysis in conscious rats. J Neural Transm. 104:1997;953-966
29. Pozzi L., Invernizzi R., Garavaglia C., Samanin R. Fluoxetine increases extracellular dopamine in the prefrontal cortex by a mechanism not dependent on serotonin A comparison with citalopram. J Neurochem. 73:1999;1051-1057
30. Ramirez O.A., Wang R.Y. Locus coeruleus norepinephrine-containing neurons Effects produced by acute and subchronic treatment with antipsychotic drugs and amphetamine. Brain Res. 362:1986;165-170
31. Ring B.J., Catlow J., Lindsay T.J., Gillespie T., Roskos L.K., Cerimele B.J., et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther. 276:1996;658-666
32. Shelton R.C. The use of antidepressants in novel combination therapies. J Clin Psychiatry. 64:(suppl 2):2003;14-18
33. Shelton R.C., Tollefson G.D., Tohen M., Stahl S., Gannon K.S., Jacobs T.G., et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 158:2001;131-134
34. Souto M., Monti J.M., Altier H. Effects of clozapine on the activity of central dopaminergic and noradrenergic neurons. Pharmacol Biochem Behav. 10:1979;5-9
35. Szabo S.T., Blier P. Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons. Brain Res. 922:2001;9-20
36. 2A receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther. 302:2002;983-991
37. Szabo S.T., de Montigny C., Blier P. Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br J Pharmacol. 126:1999;568-571
38. Szabo S.T., de Montigny C., Blier P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol. 3:2000;1-11
39. Tanda G., Carboni E., Frau R., Di Chiara G. Increase of extracellular dopamine in the prefrontal cortex A trait of drugs with antidepressant potential? Psychopharmacology. 115:1994;285-288
40. Thase M.E. What role do atypical antipsychotic drugs have in treatment-resistant depression? J Clin Psychiatry. 63:2002;95-103
41. Tohen M., Vieta E., Calabrese J., Ketter T.A., Sachs G., Bowden C., et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 60:2003;1079-1088
42. Viner M.W., Chan Y., Bakshi I., Kamper P. Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation. J Clin Psychopharmacol. 23:2003;104-106
43. Westerink B.H., de Boer P., de Vries J.B., Kruse C.G., Long S.K. Antipsychotic drugs induce similar effects on the release of dopamine and noradrenaline in the medial prefrontal cortex of the rat brain. Eur J Pharmacol. 361:1998;27-33
44. Williamson D.J., Anderson S.W., Van Campen L.E., Paul S., Tollefson G.D. Olanzapine-fluoxetine combination for difficult depressions. World J Biol Psychiatry. 2:2001;104S
45. Xu Z.-Q.D., Shi T.-J.S., Hokfelt T. Galanin/GMAP-and NPY-like immunoreactivities in locus coeruleus and noradrenergic nerve terminals in the hippocampal formation and cortex with notes on galanin-R1 and -R2 receptors. J Comp Neurol. 392:1998;227-251
46. 2A and muscarinic receptors. Psychopharmacology. 141:1999;267-278
47. Zhang W., Perry K.W., Wong D.T., Potts B.D., Bao J., Tollefson G.D., et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 23:2000;250-262